The long-accepted biochemical biomarkers of AD are low CSF Aβ42 concentrations, reflecting brain Aβ deposition, and markers of neuronal degeneration or injury, such as elevated CSF tau. The gene discussed is MAPT; the disease is Alzheimer disease.